Engineered immune cells take aim at Hard-to-Treat leukemias
NCT ID NCT06006403
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This trial is testing a new type of immune cell therapy called CD123 CAR-NK cells in people with relapsed or refractory acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). The cells are designed to find and attack cancer cells that carry a protein called CD123. The study aims to see if this treatment is safe and effective, and to find the best dose. Participants receive the cells through an IV after a short course of conditioning chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD123-targeted CAR-NK cells (a type of immune cell therapy)
- What this could lead to
- If successful, this could lead to a new treatment option for people with hard-to-treat AML or BPDCN, potentially offering a path to remission.
- What could go wrong
- This is an early-phase trial with only 5 participants, so results may not apply broadly. There are risks of side effects, and the therapy may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?